{"name":"LMC Diabetes & Endocrinology Ltd.","slug":"lmc-diabetes-endocrinology-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"150% bolus insulin correction","genericName":"150% bolus insulin correction","slug":"150-bolus-insulin-correction","indication":"Other","status":"marketed"},{"name":"Basal insulin glargine and lixisenatide","genericName":"Basal insulin glargine and lixisenatide","slug":"basal-insulin-glargine-and-lixisenatide","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SGLT2 inhibitor and DPP-4 inhibitor","genericName":"SGLT2 inhibitor and DPP-4 inhibitor","slug":"sglt2-inhibitor-and-dpp-4-inhibitor","indication":"Type 2 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"150% bolus insulin correction","genericName":"150% bolus insulin correction","slug":"150-bolus-insulin-correction","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Basal insulin glargine and lixisenatide","genericName":"Basal insulin glargine and lixisenatide","slug":"basal-insulin-glargine-and-lixisenatide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SGLT2 inhibitor and DPP-4 inhibitor","genericName":"SGLT2 inhibitor and DPP-4 inhibitor","slug":"sglt2-inhibitor-and-dpp-4-inhibitor","phase":"marketed","mechanism":"This combination drug lowers blood glucose by blocking kidney glucose reabsorption (SGLT2 inhibitor) and slowing incretin hormone breakdown (DPP-4 inhibitor).","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQRk5pc1FSRGVhc1V6T2VjRDhVVEZCLXJrT0Vscll1VkxwX25KdEU0UWJTb281TFl4SXFlMzFsRXFJY0xpQm5MeHozNkx1alRZOVRkbTFQQ3Y0RlhOSzZORTdyeG9LS3ZHblVvOXF5QjhfemRfTV8zZi1Wal9mNVkzbS1FWEM4N19GMEZOV0dnSDA4UmpTWlJaMHpwTWNiclRqUXdpNlJ5dTh0WElFYmtqNm1BZWUzUG9xdGtKa0h1aEdSdFNacE9sVTZ0MDFOVndtR2lYZ3VSSjBmMW1pT3hDcnAxWnE3dFNzMFE?oc=5","date":"2024-11-26","type":"deal","source":"Newswire Canada","summary":"Collaboration achieves significant health gains for high-risk participants in type 2 diabetes program - Newswire Canada","headline":"Collaboration achieves significant health gains for high-risk participants in type 2 diabetes program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRkZLdUhmb25pNVc4aW44Z2t5cWdrMTRQZURILUdhU1IycUh5bmhyaVVHN1U2NVdMUEt6cTgtNDZSb2x5cFdKeWVaOHNpM1VlMm5JaS1pV1BRSWJtVEtxcmhWazVhYkJ3ZnZjdUpIUU9qMFlGM2s3VUUwcFpXZUJyLVRmQkppa1ExeThDdTNKV1BLOFlsRWZuaGtYZ1pPajNBcjZtYkNhWDc?oc=5","date":"2022-02-10","type":"pipeline","source":"Clinical Leader","summary":"Canada's Largest Bypass Project Lands At Canada's Largest Airport - Clinical Leader","headline":"Canada's Largest Bypass Project Lands At Canada's Largest Airport","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPdXhEVVdhZ2wzNFBpdlVieGEyakJrU0NhZ0xScWozOWlZdllqVXNOTXZ1Mm5GSHM3aGdXc3o0M3Z3VV9lZDRSb1M4NERQN3JyZktMOEw4OVQwbnY0cHlqVUtIelFVc0hsQ3dMR1AtSmlDR3Vtbkg3V1NtajFQUjMwY3FxWGt0dk51aHhXMGgyYw?oc=5","date":"2014-05-27","type":"regulatory","source":"drugdiscoverytrends.com","summary":"Canada Approves Janssen’s Novel Diabetes Treatment - drugdiscoverytrends.com","headline":"Canada Approves Janssen’s Novel Diabetes Treatment","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}